3.3 million for the 1st eight weeks. On average that would equate to 21 million sales for the first year. That is a significant first year number given the CSSI label designation. That number may also increase as more health care professionals become familiar with or exposed to the benefits of this drug.
In my opinion a key comment from the CC was the statement that the reorders were 50% larger than the initial orders. This would indicate that not only is the product being used and not just 'sitting on the shelf' but the purchasers are anticipating a significant increase in useage.
"CC shows great future for Cubist" ===================================================== They're just not going to tell you about it!
Sounds like many investors and analysts are getting frustrated over management's refusal to give guidance. Management would have you believe they are just being prudent due to the unique characteristics of their product launch, but when one analyst sought weekly sales trends thus far for 2004, they refused to even provide this.
Why? Because the trends aren't comforting. They reported 2004 sales to date (thru yesterday) of 3.3M. This covers exactly an 8 week period....working out to an average of 400K sales per week. Well, earlier this year they bragged about having 400K in sales in the first week of 2004. Obviously the weekly sales trends aren't very positive, so their just not going to disclose them.